CA
NZ
UK
AU
IND
US
United Health Products (OTC: UEEC) has secured a regulatory sponsor for its upcoming clinical study. The company announced on July 7, 2026, that NAMSA, a global MedTech contract research organization, will oversee the trial for its CelluSTAT Hemostatic Gauze. This collaboration is part of …
Viking Therapeutics (NASDAQ: VKTX) saw its stock move lower during active trading as investors reconsidered the company’s technical position. The shift followed discussions of a possible double-top pattern, a chart formation that, if confirmed, may suggest a short-term reversal. While the company’s underlying business …
AppTech Payments Corp. Announced a leadership transition, appointing its Chief Financial Officer, Felipe Corrado, to serve as interim chief executive officer. The change was detailed in a recent filing with the U.S.
Autonomix Medical, Inc. (NASDAQ: AMIX) reported that it has satisfied Nasdaq’s minimum bid‑price requirement after a brief period of non‑compliance. The company confirmed that its common shares traded at a price not less than $1.00 for ten successive trading sessions, ending the recent compliance …
Carasent AB announced strong second‑quarter results that signal strengthening momentum for providers of HR and platform solutions in the healthcare sector. The combination of a high proportion of recurring revenue and solid growth metrics is likely to lift sentiment across European health‑tech equities and …
Cosmos Health Inc. Has introduced a subscription-based sales model for its proprietary NOOR Collagen product, marking a strategic shift toward recurring revenue in the wellness sector. This move could influence competitors in the nutritional supplements and personal care industries to explore similar models, potentially …
Cosmos Health (NASDAQ: COSM) announced a new subscription service for its NOOR Collagen health product in the United States. The initiative aims to lock in recurring demand and strengthen margins, positioning the firm against competing over‑the‑counter supplements.
InnoCare Pharma’s experimental BTK inhibitor orelabrutinib delivered breakthrough efficacy in systemic lupus erythematosus (SLE), sending ripples through autoimmune disease drug developers and lifting biotech sector sentiment. The Phase IIb results, published in the Journal of Autoimmunity on July 10, 2026, showed the drug’s potential …
Palisade Bio Inc. (NASDAQ: PALI) disclosed that its chief executive, JD Finley, and president/C MO Dr. Mitchell Jones will join the Leerink Partners Therapeutics Forum in Boston on July 14‑15. The appearance comes as the company prepares to advance its lead candidate, PALI‑2108, into …
Analysts view the acknowledgment as a catalyst for increased investment in platforms that blend real‑time engagement with predictive analytics, potentially uplifting the broader technology and artificial‑intelligence sectors.
Please wait processing your request...